The Nuclear Medicine Radiopharmaceuticals Market size is expected to grow at an annual average of 3% during 2021-2027. Radiopharmaceuticals are pharmaceutical preparations containing radioactive isotopes used for diagnosis and treatment. Simple, small substances containing radioactive substances used to treat cancer and heart and nerve disorders.
(Get 15% Discount on Buying this Report)
A full report of Nuclear Medicine Radiopharmaceuticals Market is available at: https://www.orionmarketreports.com/nuclear-medicine-radiopharmaceuticals-market/29968/
The following segmentation are covered in this report:
By Application
- Oncology
- Cardiology
- Neurology
- Thyroid
- Others
By End-user
- Hospitals and diagnostic centers
- Research institutes
By Procedures
- Oncology
- Cardiovascular
- Central Nervous System
- Endocrine
- Skeletal
- Gastrointestinal
- Genito-urinary
- Pulmonary
- PET & PET-CT
- Therapeutic
- Others
Company Profile
- Curium Pharma (France)
- Bayer Group (Germany)
- GE Healthcare (U.S.)
- Cardinal Health (U.S.)
- Jubilant Life science (India)
- Lantheus Medical Imaging (U.S.)
- Novartis International AG (Advanced accelerator) (Switzerland)
- South African Nuclear Energy Corporation (NTP Radioisotopes SOC Ltd) (South Africa)
- Fujifilm Holding Corporation (Japan)
The report covers the following objectives:
- Proliferation and maturation of trade in the global Nuclear Medicine Radiopharmaceuticals Market
- The market share of the global Nuclear Medicine Radiopharmaceuticals Market supply and demand ratio, growth revenue, supply chain analysis, and business overview.
- Current and future market trends that are influencing the growth opportunities and growth rate of the Nuclear Medicine Radiopharmaceuticals Market
- Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Nuclear Medicine Radiopharmaceuticals Market
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
